WO2001022991A1 - Traitement a l'acth de patients recevant des steroides et des statines - Google Patents

Traitement a l'acth de patients recevant des steroides et des statines Download PDF

Info

Publication number
WO2001022991A1
WO2001022991A1 PCT/SE2000/001880 SE0001880W WO0122991A1 WO 2001022991 A1 WO2001022991 A1 WO 2001022991A1 SE 0001880 W SE0001880 W SE 0001880W WO 0122991 A1 WO0122991 A1 WO 0122991A1
Authority
WO
WIPO (PCT)
Prior art keywords
acth
patient
statins
therapy
fragments
Prior art date
Application number
PCT/SE2000/001880
Other languages
English (en)
Inventor
Anna-Lena Berg
Margret Arnadottir
Original Assignee
Berg Anna Lena
Margret Arnadottir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Anna Lena, Margret Arnadottir filed Critical Berg Anna Lena
Priority to AU76975/00A priority Critical patent/AU7697500A/en
Publication of WO2001022991A1 publication Critical patent/WO2001022991A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • the active ingredient of the therapeutic composition is ACTH including fragments thereof.
  • fragments as used herein means ACTH from which amino acids in the sequence have been “cut off” to such an extent that the therapeutic effect of the fragments is at least equal to that of the ACTH.
  • Synacthen Ciba-Geigy, Basel, Switzerland
  • 1-24 N-terminal fragment of ACTH.
  • preparations comprising fragments of ACTH are commer- cially available. The selection thereof for the purpose of the invention is within the purview of one skilled in the art, i.e. a physician.
  • the amount of the therapeutically active ingredient that is administered and the dosage regimen for treating a disease condition with the composition depends on a variety of factors, including the age, weight, sex and medical condition of the patient, the severity of the disease, the route and frequency of administration, and the particular compound employed, and thus may vary widely. Thus, a skilled physician is able to determine the appropriate dosage considering the factors mentioned above. By way of example the following treatment scheme may be mentioned:
  • the preparation is Synacthen Depot, which is given by an intramuscular injection.
  • Month 1 1 mg once a week
  • an intramuscular injection of 1 mg ACTH, or fragments thereof, twice a week is associated with significant long-term improvements of the blood fat contents in serum in patients who are on therapy on steroids and statins.
  • a preparation of ACTH or fragments thereof is injected sub- cutaneously.
  • injectable preparations can contain such carriers or diluents as water, saline, dextrose, etc, which are preferable isotonic and sterile.
  • a preparation of ACTH or fragments thereof is administered through the nasal route.
  • the ACTH preparation is most preferably sold in a package containing a disposable syringe having said preparation present therein.
  • the preparation is contained in an inhaling device such as a spray device .
  • the preferred route is the intramuscular, subcutaneous and the nasal route.
  • Example 1 Ten patients were studied. They were all hyper- lipidemic (LDL cholesterol>3.5 mmol/L) in spite of ongoing treatment with Simvastatin (Zocord) at the maximal recommended dose i.e., 40 mg daily, and dietary advice. In all cases, the hyperlipidemia was probably primary since there was no, evidence of secondary influence on the lipoprotein metabolism (such as renal or endocrinological disease) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode de traitement de patient en cours de soin avec des stéroïdes et des statines. Cette méthode consiste à administrer au patient une quantité effective, sur le plan thérapeutique, d'une composition contenant de l'ACTH ou des fragments de celle-ci. L'invention concerne aussi l'utilisation de la composition ainsi qu'un article manufacturé, contenant la composition thérapeutique, utile pour mettre en oeuvre la méthode.
PCT/SE2000/001880 1999-09-29 2000-09-29 Traitement a l'acth de patients recevant des steroides et des statines WO2001022991A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU76975/00A AU7697500A (en) 1999-09-29 2000-09-29 Acth treatment of steroid- and statin-treated patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15659099P 1999-09-29 1999-09-29
US60/156,590 1999-09-29

Publications (1)

Publication Number Publication Date
WO2001022991A1 true WO2001022991A1 (fr) 2001-04-05

Family

ID=22560203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/001880 WO2001022991A1 (fr) 1999-09-29 2000-09-29 Traitement a l'acth de patients recevant des steroides et des statines

Country Status (2)

Country Link
AU (1) AU7697500A (fr)
WO (1) WO2001022991A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040032A3 (fr) * 2007-09-11 2009-05-22 Mondobiotech Lab Ag Utilisation d'un peptide en tant qu'agent thérapeutique

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A.-L. BERG ET AL.: "ACTH 1-24 decreases hepatic lipase activities and low density lipoprotein concentrations in healthy men", JOURNAL OF INTERNAL MEDICINE, vol. 229, 1991, pages 201 - 203, XP002935312 *
A.-L. BERG ET AL.: "Regulation of hepatic lipase secretion from Hep G2 cells by ACTH and corticosteroids", HORM. METAB. RES., vol. 29, 1997, pages 475 - 476, XP002935315 *
BERG ANNA-LENA ET AL.: "ACTH revisited-potential implications for patients with renal disease", NEPHROL. DIAL. TRANSPLANT, vol. 15, July 2000 (2000-07-01), pages 940 - 942, XP002935317 *
BERG ANNA-LENA ET AL.: "Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy", KIDNEY INTERNATIONAL, vol. 56, October 1999 (1999-10-01), pages 1534 - 1543, XP002935316 *
DATABASE FILE CAPLUS [online] BERG ANNA-LENA ET AL.: "ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney desease", retrieved from 125:158195 accession no. STN International Database accession no. 1996:519022 *
KIDNEY INT., vol. 50, no. 2, 1996, pages 538 - 542 *
MARGRET ARNADOTTIR ET AL.: "Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients", KIDNEY INTERNATIONAL, vol. 52, 1997, pages 1651 - 1655, XP002935314 *
MARGRET ARNADOTTIR ET AL.: "Corticotropin-induced reduction of plasma lipoprotein(a) concentrations in healthy individuals and hemodialysis patients: Relation to apolipoprotein(a) size polymorphism", METABOLISM, vol. 48, no. 3, March 1999 (1999-03-01), pages 342 - 346, XP002935313 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040032A3 (fr) * 2007-09-11 2009-05-22 Mondobiotech Lab Ag Utilisation d'un peptide en tant qu'agent thérapeutique

Also Published As

Publication number Publication date
AU7697500A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
US5574010A (en) Treatment of pancreatic tumors with peptide YY and analogs thereof
KR100343314B1 (ko) 만성통증치료에유용한레보부피바카인
AU645874B2 (en) Treatment for osteoporosis using growth hormone release factor (GRF) in combination with parathyroid hormone (PTH)
UA32636C2 (uk) Засіб для зниження вмісту холестерину в сироватці крові людини
NZ227857A (en) Pharmaceutical composition of igf-i and insulin for treating or preventing secondary effects of hyperinsulinemia
DK177177B1 (da) Lindring af Peyronie's sygdom
CN1610551A (zh) 用作止痛剂的6－羟基羟吗啡酮的肠胃外给药
JP2007246530A (ja) エリトロポエチン及び修飾ヘモグロビンを含んでいる医薬配合製剤
KR950703951A (ko) 광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통과 해열치료에 이를 사용하는 방법(antipyretic and analgesic methods and compositions containing optically pure r-ketorolac)
AU666514B2 (en) Method and composition for the treatment of osteoporosis
CA2142455A1 (fr) Methode de traitement general des pathologies cataboliques et des blessures aux tissus de l'organisme
KR920700227A (ko) 초고활성 인체 인슐린 동족체
WO2001022991A1 (fr) Traitement a l'acth de patients recevant des steroides et des statines
Burgess et al. Thoracic epidural anesthesia for transsternal thymectomy in myasthenia gravis
US20040242489A1 (en) Method for improving stability of a bone-connecting implant
Hudson et al. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease
EP0828507A1 (fr) Technique de traitement de la douleur
US8053409B2 (en) Agent for prophylaxis of reflex sympathetic dystrophy after cerebral apoplexy
JP2002536337A (ja) 麻酔の調節
US5725860A (en) Method for reducing the risk of developing diabetes
WO1997003689A1 (fr) Procede de traitement de l'epilepsie au moyen du facteur neurotrophique derive du cerveau
US20020147137A1 (en) Medical use of alpha1-acid glycoprotein (AAG) or orosomucoid
West et al. Ankylosing spondylitis and prolonged ACTH therapy
WO2024042518A1 (fr) Antagoniste du récepteur glp-1 et ses procédés d'utilisation
UA22090A (uk) Спосіб лікуваhhя раhової хвороби

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP